<DOC>
	<DOCNO>NCT02118168</DOCNO>
	<brief_summary>An observational study prospectively follow-up patient enrol ISS T-002 clinical trial 132 week . The primary endpoint study evaluate persistence , term frequency , magnitude quality , anti-Tat humoral cellular immune response HIV-1 infected individual participate ISS T-002 receive least 3 immunization . The secondary endpoint define validate novel laboratory test future efficacy clinical trial .</brief_summary>
	<brief_title>Observational Study Extended Follow-up Patients Enrolled Therapeutic Clinical Trial ISS T-002</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Previous participation ISS T002 trial , receive least 3 immunization ; A followup least 48 week ISS T002 study ; Availability participate extend followup study ; Signed informed consent . The absence criterion exclude subject study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HAART</keyword>
	<keyword>Tat Protein</keyword>
</DOC>